We proudly present the 5th Annual
Ophthalmic Drugs Conference taking place on the 21st-22nd of November 2022, in London.
The
Ophthalmic drugs industry continues to expand year on year, with an ageing population there is continual demand for advancements in ophthalmic treatments. At the forefront of our 5th annual event will be a variety of novel drugs which are showing good clinical trial data. Drug delivery will also be an important aspect of the agenda, with advancements in novel technologies. Other key areas will be gene therapy and Artificial Intelligence with developments on the latest drug pipelines and clinical trials.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior drug delivery Engineers, Device Testing Managers, Heads of Late-Stage Development, Clinical trial directors and much more.
As our 5th annual event we look forward to welcoming you back to the conference in November.
Early registration is strongly advised to avoid disappointment.
Benefits of Attending
- Assess new industry directions through the latest data from ophthalmic clinical trials
- Review advanced techniques in treating age-related diseases of ophthalmology
- Explore evolving therapeutic potential in undruggable diseases through innovative gene therapies
- Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field
- Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D
Who should attend
- CEOs, CMOs and Researchers from pharmaceutical companies involved in ocular drug development, in addition to biotechnologies involved in ocular drug delivery research.
- Heads and VPs of Retinal Health, Ocular Therapy, Medical Safety, and Ophthalmology.
- Professors, Senior Lecturers, and Specialists in Ocular biology and immunology, and clinical pharmaceuticals.
Speakers
- Aniz Girach, Chief Medical Officer, ProQR Therapeutics
- Catherine Wyman, Head of Eyecare, TTP Plc
- Daniel Chao, Senior Director and Clinical lead, Translational Medicine and Early Clinical Development, Janssen Research and Development
- Daniel Chung, Chief Medical Officer, Sparing Vision
- Daniela Ferrara, Principal Medical Director, Genentech / Roche
- Daniyar Dauletbekov, Medical Director, Roche Products Ltd
- Daniela Ferrara, Principal Medical Director, Genentech / Roche
- David J Tanzer, Chief Medical Officer, Executive Vice President , OcuTerra Therapeutics
- Francesca Cordeiro, Professor of Retinal Neurodegeneraton and Glaucoma studies, UCL
- Katie Binley, Chief Scientific Officer, Ikarovec
- Loic Lhuillier, COO, Exonate
- Magali Taiel, Chief Medical Officer , GenSight Biologics
- Marion Munk, Chief Medical Officer, Isarna Therapeutics
- Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
- Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
- Nathan Wilkinson, Ophthalmic Innovation Lead, TTP Plc
- Omar Sadruddin, Therapeutic Area Head, Glaucoma, Santen Pharmaceutical
- Pearse Keane, Consultant, Moorfields Eye Hospital NHS Foundation Trust
- Peter Morgan-Warren, Therapy Area Head Ophthalomolgy, Bayer PLC
- Viral Kansara, Vice President of Preclinical Development, Clearside Biomedical
- Virginia Calder, Professor of Ocular Immunology, UCL Institute of Ophthalmology
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
